社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
G7
IP属地：未知
+关注
帖子 · 44
帖子 · 44
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
G7
G7
·
2021-12-31
$Razer(01337)$
New Year soon... Good news when?
看
734
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
G7
G7
·
2021-12-24
$Razer(01337)$
News when? lol
看
864
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
G7
G7
·
2021-12-14
lower more please
Why Nvidia Stock Keeps Dropping
Nvidia has been a big gainer, but now other, smaller chip stocks look cheaper.
Why Nvidia Stock Keeps Dropping
看
739
回复
评论
点赞
6
编组 21备份 2
分享
举报
G7
G7
·
2021-12-02
for real?
Razer will be privatized at a price of HK $2.82 per share
A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10
Razer will be privatized at a price of HK $2.82 per share
看
682
回复
评论
点赞
6
编组 21备份 2
分享
举报
G7
G7
·
2021-11-24
$Razer(01337)$
come on baby
看
714
回复
评论
点赞
4
编组 21备份 2
分享
举报
G7
G7
·
2021-11-22
good
Fujifilm to spend $5bn to become global contract drugmaker
Opportunity seen in outsourcing trend similar to chip industry Fujifilm plans to introduce a new pro
Fujifilm to spend $5bn to become global contract drugmaker
看
774
回复
2
点赞
5
编组 21备份 2
分享
举报
G7
G7
·
2021-11-17
$Nanofilm(MZH.SI)$
lol what happened? pleasant surprise
看
1,731
回复
2
点赞
4
编组 21备份 2
分享
举报
G7
G7
·
2021-11-17
$Razer(01337)$
let's go
看
800
回复
评论
点赞
4
编组 21备份 2
分享
举报
G7
G7
·
2021-11-16
$Razer(01337)$
oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK
看
1,333
回复
评论
点赞
1
编组 21备份 2
分享
举报
G7
G7
·
2021-11-16
$Razer(01337)$
Nice
看
821
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575098910724577","uuid":"3575098910724577","gmtCreate":1612004886936,"gmtModify":1629104032528,"name":"G7","pinyin":"g7","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":95,"tweetSize":44,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.13","exceedPercentage":"60.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692879309,"gmtCreate":1640924904201,"gmtModify":1640924913424,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> New Year soon... Good news when?","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> New Year soon... Good news when?","text":"$Razer(01337)$ New Year soon... Good news when?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692879309","isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698111072,"gmtCreate":1640316263012,"gmtModify":1640316650415,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> News when? lol","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> News when? lol","text":"$Razer(01337)$ News when? lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698111072","isVote":1,"tweetType":1,"viewCount":864,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607991523,"gmtCreate":1639469048269,"gmtModify":1639469048428,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"lower more please","listText":"lower more please","text":"lower more please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607991523","repostId":"1193701389","repostType":2,"repost":{"id":"1193701389","kind":"news","pubTimestamp":1639460770,"share":"https://www.laohunote.com/m/news/1193701389?lang=&edition=full","pubTime":"2021-12-14 13:46","market":"us","language":"en","title":"Why Nvidia Stock Keeps Dropping","url":"https://stock-news.laohu8.com/highlight/detail?id=1193701389","media":"Motley Fool","summary":"Nvidia has been a big gainer, but now other, smaller chip stocks look cheaper.","content":"<p><b>What happened</b></p>\n<p>Shares of semiconductor company <b>Nvidia</b> dropped again on Monday -- down 6.8% as of closed -- its fourth straight down day in a row. There doesn't appear to be any particular news behind today's decline, at least not specific to Nvidia.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fe9777cd8866f53c260abe399593d3d0\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p><b>So what</b></p>\n<p>From a big picture perspective, the news isn't great. CNBC reported this morning there's a risk that the ongoing chip shortage could depress Christmas shopping this year.</p>\n<p>Although high demand for high-end Nvidia graphics chips is generally good news for the company and its pricing power, the network notes that \"semiconductors are beneath the hood of an increasing number of products,\" but \"things made with chips don't just use one chip.\" Thus, even a PC manufacturer lucky enough to get hold of all the Nvidia chips it needs might not be able to sell its PC if it can't also get all the power control, memory, and other chips it also needs to build the product. Or the manufacturer might not buy the Nvidia chips in the first place if it knows it won't be able to obtain the other chips.</p>\n<p><b>Now what</b></p>\n<p>That's one risk Nvidia investors face. A bigger risk, though, may be its high-flying stock price.</p>\n<p>This morning, analysts at <b>JPMorgan</b>, at <b>UBS</b>, at <b>Barclays</b>,<b>Citigroup</b>, R.W. Baird, and <b>Evercore</b> ISI cited a range of semiconductor chipmakers that they like and believe are undervalued, and Nvidia wasn't one of them. Morgan recommended <b>Qualcomm</b> for its earnings upside, Evercore picked <b>Micron</b> as a stock that is \"structurally undervalued,\" and Barclays, Baird, and Citi raised their price targets on <b>Broadcom</b> based on demand for its products,TheFly.com reported today.</p>\n<p>Nvidia shares sell for 93 times trailing earnings. Micron is valued at less than 17 times earnings; Qualcomm is at 23 times, and Broadcom is at 47. It's pretty clear why Wall Street might consider these stocks relatively better deals than Nvidia.</p>\n<p>And it's just as clear why some investors might have decided that now is a good time to cash out some Nvidia stock winnings, and reinvest them in relatively cheaper stocks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Nvidia Stock Keeps Dropping</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Nvidia Stock Keeps Dropping\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 13:46 GMT+8 <a href=https://www.fool.com/investing/2021/12/13/why-nvidia-stock-keeps-dropping/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of semiconductor company Nvidia dropped again on Monday -- down 6.8% as of closed -- its fourth straight down day in a row. There doesn't appear to be any particular news behind ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/13/why-nvidia-stock-keeps-dropping/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/12/13/why-nvidia-stock-keeps-dropping/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193701389","content_text":"What happened\nShares of semiconductor company Nvidia dropped again on Monday -- down 6.8% as of closed -- its fourth straight down day in a row. There doesn't appear to be any particular news behind today's decline, at least not specific to Nvidia.\nImage source: Getty Images.\nSo what\nFrom a big picture perspective, the news isn't great. CNBC reported this morning there's a risk that the ongoing chip shortage could depress Christmas shopping this year.\nAlthough high demand for high-end Nvidia graphics chips is generally good news for the company and its pricing power, the network notes that \"semiconductors are beneath the hood of an increasing number of products,\" but \"things made with chips don't just use one chip.\" Thus, even a PC manufacturer lucky enough to get hold of all the Nvidia chips it needs might not be able to sell its PC if it can't also get all the power control, memory, and other chips it also needs to build the product. Or the manufacturer might not buy the Nvidia chips in the first place if it knows it won't be able to obtain the other chips.\nNow what\nThat's one risk Nvidia investors face. A bigger risk, though, may be its high-flying stock price.\nThis morning, analysts at JPMorgan, at UBS, at Barclays,Citigroup, R.W. Baird, and Evercore ISI cited a range of semiconductor chipmakers that they like and believe are undervalued, and Nvidia wasn't one of them. Morgan recommended Qualcomm for its earnings upside, Evercore picked Micron as a stock that is \"structurally undervalued,\" and Barclays, Baird, and Citi raised their price targets on Broadcom based on demand for its products,TheFly.com reported today.\nNvidia shares sell for 93 times trailing earnings. Micron is valued at less than 17 times earnings; Qualcomm is at 23 times, and Broadcom is at 47. It's pretty clear why Wall Street might consider these stocks relatively better deals than Nvidia.\nAnd it's just as clear why some investors might have decided that now is a good time to cash out some Nvidia stock winnings, and reinvest them in relatively cheaper stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603657271,"gmtCreate":1638408014836,"gmtModify":1638408015063,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"for real? ","listText":"for real? ","text":"for real?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603657271","repostId":"1197247033","repostType":2,"repost":{"id":"1197247033","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638406745,"share":"https://www.laohunote.com/m/news/1197247033?lang=&edition=full","pubTime":"2021-12-02 08:59","market":"hk","language":"en","title":"Razer will be privatized at a price of HK $2.82 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1197247033","media":"Tiger Newspress","summary":"A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10","content":"<p>A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10.79 billion Hong Kong dollars (US$1.38 billion) to take the Hong Kong-listed company private.</p>\n<p>Private-equity firm CVC Capital Partners is part of the consortium, Razer said Thursday in a filing to the Hong Kong bourse.</p>\n<p>The consortium is offering HK$2.82 a share to buy all shares it doesn't currently hold, representing a 5.6% premium to the stock's last closing price. The offer is final, Razer said.</p>\n<p>Razer, which sells gear for gamers such as keyboards and headphones and has bases in California and Singapore, was founded in 2005 and went public in 2017. Shares are up 12% this year, but remain well below their initial public offering price.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Razer will be privatized at a price of HK $2.82 per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRazer will be privatized at a price of HK $2.82 per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 08:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10.79 billion Hong Kong dollars (US$1.38 billion) to take the Hong Kong-listed company private.</p>\n<p>Private-equity firm CVC Capital Partners is part of the consortium, Razer said Thursday in a filing to the Hong Kong bourse.</p>\n<p>The consortium is offering HK$2.82 a share to buy all shares it doesn't currently hold, representing a 5.6% premium to the stock's last closing price. The offer is final, Razer said.</p>\n<p>Razer, which sells gear for gamers such as keyboards and headphones and has bases in California and Singapore, was founded in 2005 and went public in 2017. Shares are up 12% this year, but remain well below their initial public offering price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01337":"雷蛇"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197247033","content_text":"A consortium led by the founders of gaming equipment maker Razer Inc. have made an offer of up to 10.79 billion Hong Kong dollars (US$1.38 billion) to take the Hong Kong-listed company private.\nPrivate-equity firm CVC Capital Partners is part of the consortium, Razer said Thursday in a filing to the Hong Kong bourse.\nThe consortium is offering HK$2.82 a share to buy all shares it doesn't currently hold, representing a 5.6% premium to the stock's last closing price. The offer is final, Razer said.\nRazer, which sells gear for gamers such as keyboards and headphones and has bases in California and Singapore, was founded in 2005 and went public in 2017. Shares are up 12% this year, but remain well below their initial public offering price.","news_type":1},"isVote":1,"tweetType":1,"viewCount":682,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874383653,"gmtCreate":1637730690136,"gmtModify":1637730690211,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>come on baby","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>come on baby","text":"$Razer(01337)$come on baby","images":[{"img":"https://static.tigerbbs.com/ad7a73051ad66984ade34ca81e8216ac","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874383653","isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":872551136,"gmtCreate":1637550625535,"gmtModify":1637550650552,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872551136","repostId":"1108872503","repostType":4,"repost":{"id":"1108872503","kind":"news","pubTimestamp":1637550331,"share":"https://www.laohunote.com/m/news/1108872503?lang=&edition=full","pubTime":"2021-11-22 11:05","market":"us","language":"en","title":"Fujifilm to spend $5bn to become global contract drugmaker","url":"https://stock-news.laohu8.com/highlight/detail?id=1108872503","media":"Nikkei Asia","summary":"Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new pro","content":"<p>Opportunity seen in outsourcing trend similar to chip industry</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cffcbada03c1878d7dd688d377607e1\" tg-width=\"1400\" tg-height=\"787\" width=\"100%\" height=\"auto\"><span>Fujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)</span></p>\n<p>TOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.</p>\n<p>The Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.</p>\n<p>As in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.</p>\n<p>As new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.</p>\n<p>Another factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.</p>\n<p>Developing a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.</p>\n<p>Takahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d4e0ef42e741341d1e8a618f8564c23\" tg-width=\"770\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Fujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)</span></p>\n<p>In fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.</p>\n<p>Research and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.</p>\n<p>In particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth</p>\n<p>Fujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"</p>\n<p>Fujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.</p>\n<p>Continuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.</p>\n<p>Takatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.</p>\n<p>Fujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujifilm to spend $5bn to become global contract drugmaker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujifilm to spend $5bn to become global contract drugmaker\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 11:05 GMT+8 <a href=https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker><strong>Nikkei Asia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K...</p>\n\n<a href=\"https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FUJIF":"FUJIFILM Holdings Corp."},"source_url":"https://asia.nikkei.com/Business/Health-Care/Fujifilm-to-spend-5bn-to-become-global-contract-drugmaker","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108872503","content_text":"Opportunity seen in outsourcing trend similar to chip industry\nFujifilm plans to introduce a new production system that can produce antibodies with high purity more efficiently at its plant in the U.K. (Photo courtesy of Fujifilm)\nTOKYO -- Fujifilm Holdings is staking its future on becoming a provider of drug development and manufacturing services to other pharmaceutical companies.\nThe Japanese company is spending 600 billion yen ($5.25 billion) to gain a foothold in a market that is expected to grow rapidly in the coming years. It decided at the end of June to increase its investment by 90 billion yen, betting that it can become the pharmaceutical industry's answer to Taiwan Semiconductor Manufacturing Co., which specializes in making computer chips designed by others.\nAs in the chip industry, there is a growing trend among big drugmakers to farm out some or all of their development and manufacturing to specialists. One factor driving the trend is the growing diversity of treatments and drugmaking technologies.\nAs new treatments such as antibody drugs, cell therapies and gene therapies have become widely available, pharmaceutical companies face much tougher challenges developing and marketing drugs.\nAnother factor is the huge investment needed to develop and manufacture biopharmaceuticals -- drugs derived from biological processes, such as blood products. This has opened the door for contract development and manufacturing organizations (CDMOs) of the sort Fujifilm hopes to become.\nDeveloping a new drug and bringing it to the market typically takes around 10 years and carries with it a huge risk of failure. The economics of the business argue for outsourcing: It makes sense for pharmaceutical companies to focus on lab operations drug discovery, and leaving steps such as cell line development, clinical trials and commercial manufacturing to service providers like CDMOs. \"We want to focus our management resources on drug discovery and marketing,\" says an executive at a major Japanese drugmaker.\nTakahiro Mori, a senior analyst at Mizuho Securities, predicts steady growth for outsourcing in the biopharmaceutical industry. \"Major pharmaceutical companies are putting less priority on investment in complex and sophisticated production technology for such drugs,\" he points out.\nFujifilm believes it can be a major player in contract development and manufacturing of drugs by capitalizing on its competitive production technology. (File photo by AP)\nIn fact, more big drugmakers are selling off their manufacturing operations these days. Swiss pharmaceutical giant Novartis sold its U.S. production facility for gene therapies to AGC in August. AstraZeneca of Britain sold its U.S. plant to AGC in June 2020.\nResearch and Markets has forecast the CDMO market will grow by 50% to $241 billion by 2024, compared with 2020. The market is currently dominated by Lonza Group, a Swiss company, Boehringer Ingelheim of Germany and Samsung Biologics of South Korea. Together, they control around 70% of the global market in terms of production capacity.\nIn particular, Samsung Biologics is using its financial muscle to expand, spending around $1.4 billion on a new plant that will raise its capacity by 70% next year. It has further plans for growth\nFujifilm is late to the race but hopes its competitive production technology will help it catch up. The Japanese company plans to introduce a new production system that can more efficiently make antibodies with high purity in its plant in the U.K. Fujifilm describes the system as a \"fully integrated continuous processing facility.\"\nFujifilm's continuous processing approach offers a cost-effective alternative to traditional batch cell culturing, allowing higher efficiency, along with better, more consistent product quality, the company says. Because it allows continuous production, the system does not require large tanks, reducing the required investment by 70% and overall production costs by around 30%, according to Fujifilm. The company says the amount of antibodies that can be harvested is three times higher with its continuous production method, compared with conventional batch production.\nContinuous production, however, requires highly precise control of the entire cell culturing process, as well as sophisticated refining technology and equipment. It also demands an enormous amount of culture media -- 30 to 40 times more than is used in batch production. These technological and cost challenges have hindered widespread use of continuous production for biopharmaceuticals. Fujifilm has taken advantage of its design capabilities in film production and other businesses to develop new equipment for its continuous production system.\nTakatoshi Ishikawa, a senior executive vice president in charge of the company's Bio CDMO division, calls Fujifilm's new production system \"a game-changer\" that will put it in a strong position to become the market leader. The company is already in talks with more than one major pharmaceutical company over the new technology.\nFujifilm aims to raise the sales in its CDMO business to 200 billion yen by the year through March 2025, double the figure for the year that ended in March 2021, and achieve annual sales growth of 20% in subsequent years.","news_type":1},"isVote":1,"tweetType":1,"viewCount":774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878354205,"gmtCreate":1637154040638,"gmtModify":1637154040835,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MZH.SI\">$Nanofilm(MZH.SI)$</a>lol what happened? pleasant surprise","listText":"<a href=\"https://laohu8.com/S/MZH.SI\">$Nanofilm(MZH.SI)$</a>lol what happened? pleasant surprise","text":"$Nanofilm(MZH.SI)$lol what happened? pleasant surprise","images":[{"img":"https://static.tigerbbs.com/f3bb9ca3f3e783c9a2c0d58a68a524b2","width":"1080","height":"3164"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878354205","isVote":1,"tweetType":1,"viewCount":1731,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871728191,"gmtCreate":1637114399056,"gmtModify":1637114735467,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> let's go","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> let's go","text":"$Razer(01337)$ let's go","images":[{"img":"https://static.tigerbbs.com/a26aa0846bf8111b623c3546d2a067a4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871728191","isVote":1,"tweetType":1,"viewCount":800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871126491,"gmtCreate":1637039077358,"gmtModify":1637039590331,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK ","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a> oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK ","text":"$Razer(01337)$ oooh more newshttps://www.reuters.com/article/razer-privatisation-idUSKBN2I10BK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871126491","isVote":1,"tweetType":1,"viewCount":1333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871112628,"gmtCreate":1637035943907,"gmtModify":1637035944003,"author":{"id":"3575098910724577","authorId":"3575098910724577","name":"G7","avatar":"https://static.tigerbbs.com/239026a67b093628454229400edb283a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575098910724577","authorIdStr":"3575098910724577"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>Nice","listText":"<a href=\"https://laohu8.com/S/01337\">$Razer(01337)$</a>Nice","text":"$Razer(01337)$Nice","images":[{"img":"https://static.tigerbbs.com/5a94448ca36d308564eb0f0db2bff460","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871112628","isVote":1,"tweetType":1,"viewCount":821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}